June 2026 Schrödinger, Inc. expanded its AI-powered computational drug discovery platform, introducing enhanced molecular modeling, molecular dynamics simulation, and predictive chemistry capabilities to accelerate pharmaceutical R&D.
April 2026 Researchers increasingly adopted generative AI and large language models (LLMs) alongside molecular modeling software to accelerate small-molecule design, virtual screening, and lead optimization.
January 2026 Pharmaceutical companies expanded investments in physics-based molecular simulation, free energy perturbation (FEP), and cloud-native molecular modeling platforms to reduce early-stage drug discovery timelines.
October 2025 Growing adoption of high-performance computing (HPC) and GPU-accelerated molecular simulations enabled faster protein-ligand interaction analysis and structure-based drug design.